Fennec Pharmaceuticals Inc. (FENC): Total Liabilities
$35.08M
As of 2025-12-31
$33.31M
As of 2026-06-30
+5.9%
3-year compound annual growth
+71.8%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.08M | -31.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $50.82M | +32.0% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $38.49M | +30.4% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $29.51M | +344.3% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $6.64M | +183.0% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $2.35M | +3.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $2.27M | +38.7% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $1.64M | -0.4% | 2020-02-14, Balance as of period end |
| 2017-12-31 | $1.64M | +309.0% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $402.0K | -14.6% | 2018-03-28, Balance as of period end |
| 2015-12-31 | $471.0K | -73.2% | 2017-03-29, Balance as of period end |
| 2014-12-31 | $1.76M | -45.2% | 2016-03-28, Balance as of period end |
| 2013-12-31 | $3.21M | -56.2% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $7.32M | +33.8% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $5.47M | -49.9% | 2013-04-01, Balance as of period end |
| 2010-12-31 | $10.92M | n/a | 2012-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗